Cargando…
JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations
The adaptive use of Janus kinase (JAK)-inhibitors has been suggested by rheumatology experts in the management of COVID-19. We recount the rationale behind their use in this setting, and the current evidence for and against their use in this review. JAK-inhibitors role in COVID-19 infection appears...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103822/ https://www.ncbi.nlm.nih.gov/pubmed/34109302 http://dx.doi.org/10.1097/XCE.0000000000000237 |
_version_ | 1783689371080196096 |
---|---|
author | Menshawey, Rahma Menshawey, Esraa Alserr, Ayman H.K. Abdelmassih, Antoine Fakhry |
author_facet | Menshawey, Rahma Menshawey, Esraa Alserr, Ayman H.K. Abdelmassih, Antoine Fakhry |
author_sort | Menshawey, Rahma |
collection | PubMed |
description | The adaptive use of Janus kinase (JAK)-inhibitors has been suggested by rheumatology experts in the management of COVID-19. We recount the rationale behind their use in this setting, and the current evidence for and against their use in this review. JAK-inhibitors role in COVID-19 infection appears to be multifaceted, including preventing viral endocytosis and dampening the effect of excessive chemokines. This drug class may be able to achieve these effects at already preapproved dosages. Concerns arise regarding reactivation of latent viral infections and the feasibility of their use in those with severe disease. Most interestingly, JAK-Inhibitors may also have an additional advantage for diabetic and obese populations, where the dysregulation of JAK-signal transducer and activator of transcription pathway may be responsible for their increased risk of poor outcomes. Targeting this pathway may provide a therapeutic advantage for these patient groups. |
format | Online Article Text |
id | pubmed-8103822 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-81038222021-05-07 JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations Menshawey, Rahma Menshawey, Esraa Alserr, Ayman H.K. Abdelmassih, Antoine Fakhry Cardiovasc Endocrinol Metab Review Articles The adaptive use of Janus kinase (JAK)-inhibitors has been suggested by rheumatology experts in the management of COVID-19. We recount the rationale behind their use in this setting, and the current evidence for and against their use in this review. JAK-inhibitors role in COVID-19 infection appears to be multifaceted, including preventing viral endocytosis and dampening the effect of excessive chemokines. This drug class may be able to achieve these effects at already preapproved dosages. Concerns arise regarding reactivation of latent viral infections and the feasibility of their use in those with severe disease. Most interestingly, JAK-Inhibitors may also have an additional advantage for diabetic and obese populations, where the dysregulation of JAK-signal transducer and activator of transcription pathway may be responsible for their increased risk of poor outcomes. Targeting this pathway may provide a therapeutic advantage for these patient groups. Wolters Kluwer Health 2020-10-15 /pmc/articles/PMC8103822/ /pubmed/34109302 http://dx.doi.org/10.1097/XCE.0000000000000237 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Articles Menshawey, Rahma Menshawey, Esraa Alserr, Ayman H.K. Abdelmassih, Antoine Fakhry JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations |
title | JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations |
title_full | JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations |
title_fullStr | JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations |
title_full_unstemmed | JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations |
title_short | JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations |
title_sort | jak out of the box; the rationale behind janus kinase inhibitors in the covid-19 setting, and their potential in obese and diabetic populations |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103822/ https://www.ncbi.nlm.nih.gov/pubmed/34109302 http://dx.doi.org/10.1097/XCE.0000000000000237 |
work_keys_str_mv | AT menshaweyrahma jakoutoftheboxtherationalebehindjanuskinaseinhibitorsinthecovid19settingandtheirpotentialinobeseanddiabeticpopulations AT menshaweyesraa jakoutoftheboxtherationalebehindjanuskinaseinhibitorsinthecovid19settingandtheirpotentialinobeseanddiabeticpopulations AT alserraymanhk jakoutoftheboxtherationalebehindjanuskinaseinhibitorsinthecovid19settingandtheirpotentialinobeseanddiabeticpopulations AT abdelmassihantoinefakhry jakoutoftheboxtherationalebehindjanuskinaseinhibitorsinthecovid19settingandtheirpotentialinobeseanddiabeticpopulations |